7210 results about "Hydrophobe" patented technology

A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount of a hydrophobic A polymer block made of a biodegradable polyester and a minor amount of a hydrophilic polyethylene glycol(PEG) B polymer block, having an overall average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the tri-block polymer and a drug may be uniformly contained in an aqueous phase to form a drug delivery composition. At temperatures below the gelation temperature of the tri-block polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid. The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, vaginal, transurethral, rectal, nasal, oral, pulmonary or aural delivery means and is a gel at body temperature. The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be adjusted by changing various parameters such as hydrophobic / hydrophilic component content, polymer concentration, molecular weight and polydispersity of the tri-block polymer. Because the tri-block polymer is amphiphilic, it functions to increase the solubility and / or stability of drugs in the composition.

A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a steroid as a foam. The pressurized product includes a foamable composition including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a steroid; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; v. water; and vi. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. The composition further may include a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof.

A stable solid controlled release formulation having a coating derived from an aqueous dispersion of a hydrophobic acrylic polymer includes a substrate including an active agent selected from the group consisting of a systemically active therapeutic agent, a locally active therapeutic agent, a disinfecting and sanitizing agent, a cleansing agent, a fragrance agent and a fertilizing agent, overcoated with an aqueous dispersion of the plasticized water-insoluble acrylic polymer. The formulation provides a stable dissolution of the active agent which is unchanged after exposure to accelerated storage conditions.

The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

A membrane for use in an implantable glucose sensor including at least one crosslinked substantially hydrophobic polymer and at least one crosslinked substantially hydrophilic polymer; wherein the first and second polymers are different polymers and substantially form an interpenetrating polymer network, semi- interpenetrating polymer network, polymer blend, or copolymer. The membranes are generally characterized by providing a permeability ratio of oxygen to glucose of about 1 to about 1000 in units of (mg / dl glucose) per (mmHg oxygen). Three methods of making membranes from hydrophobic and hydrophilic monomers formed into polymer networks are provided, wherein according to at least two of the methods, the monomers may be substantially immiscible with one another.

The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising:i. about 50% to about 98% of a solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, and mixtures thereof;ii. 0% to about 48% of a secondary solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, a co-solvent, a penetration enhancer and mixtures thereof;iii. a surface-active agent;iv. about 0% to about 5% by weight of at least one polymeric agent; andv. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition;wherein the composition is housed in a container and is substantially flowable, andwhich upon release expands to form a breakable foam; andwherein the foamable carrier is selected to generate a foam of good to excellent quality.The invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering such a composition to an afflicted target site.

A foamable composition includes about 2 to about 30% by weight solid particles; about 2 to about 75% by weight hydrophobic solvent; about 10 to about 85% by weight water; about 0.1% to about 5% by weight surface-active agent; about 0.1% to about 5 wt % by weight stabilizer / gelling agent; and a liquefied or compressed gas propellant in a container, which upon release provides a breakable foam suitable for topical administration.

A topical spray or foam, methods of making the formulation, and methods of use thereof, has been developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, anti-pruritic agents to minimize itching, and skin protective compounds may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein at least one of the drugs is bound to an ion-exchange resin. The use of binding resins, such as ion-exchange resins, allows drugs with incompatible solvent requirements to be prepared in a single-phase formulation.

Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Type of surface properties that are altered by the disclosed methods include by electrostatic properties, hydrophobic properties and hydrogen bonding properties.

The heat insulating composite aerogel material consists of silica aerogel, titania as infrared opacifier and reinforcing fiber in the weight ratio of 1 to 0.1-0.7 to 0.7-3. Its preparation process includes compounding sol with silanolate, surface modifier, titanolate, alcohol solvent, acid catalyst and alkaline catalyst in certain proportion; soaking fiber felt or prefabricated fiber part in the sol; and supercritical fluid drying. The material of the present invention has high blocking effect on solid heat transfer, air heat transfer and infrared radiation heat transfer, excellent hydrophobicity, simple preparation process, low cost, mechanical strength over 2 MPa, and wide application range, and may be used in strict heat protection condition in aeronautics, astronautics, military and civil uses.

The present invention provides a method of stimulating a subterranean formation penetrated by a well. The formation has a water-bearing section and a hydrocarbon-bearing section. The method includes the steps of: (a) introducing into the formation an aqueous treatment fluid containing a hydrophobically-modified relative permeability modifier, and (b) introducing an acidizing treatment fluid into the formation. The hydrophobically-modified RPM can be formed and introduced into the formation in several ways. For example, the hydrophobically-modified RPM can be the reaction product of a hydrophilic polymer and a hydrophobic compound that are capable of reacting with each other. The hydrophilic polymer is a polymer containing reactive amino groups in the polymer backbone or as pendant groups, which are capable of reacting with a hydrophobic alkyl halide compound. The hydrophobically-modified RPM can include, for example, a polymer of DMAEMA quaternized with an alkyl halide, wherein the alkyl halide has an alkyl chain length of 6 to 22 carbons.

The present invention relates to compositions and methods for treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences. The present invention comprises a therapeutic delivery composition effective for treating a disease state comprising an administerable admixture of an effective amount of a therapeutic compound capable of altering nucleic acid sequence function and an effective amount of a block copolymer having the following general formula: 1 wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by polyoxypropylene is between about 5000 and about 7000 Daltons; a is a number such that the portion represented by polyoxyethylene constitutes between about 10% to about 40% of the compound by weight; and b is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between about 60% and about 90% of the compound by weight. The present invention also includes compositions and methods using biologically active nonionic reverse block copolymers. The reverse copolymers have an inner core of polyoxypropylene (POP) that is flanked on either end by polyoxyethylene (POE). The reverse block copolymers have the following formula: 2 wherein "b" represents a number such that the molecular weight of the hydrophobe (C.sub.3H.sub.6O).sub.b is between approximately 2,000 and 10,000, and "a" represents a number such that the percentage of hydrophile (C.sub.2H.sub.4O).sub.a is between approximately 5% and 30%.

Medical articles (for instance, a drug delivery patch or an implantable or insertable medical device) are provided that comprise a release region, which in turn comprises (a) polymeric carrier comprising a polymer (for instance, a hydrophobic polymer) and (b) drug loaded nanoparticles, which are dispersed within the polymeric carrier. The drug loaded nanoparticles comprise a layered silicate material (for instance synthetic or naturally occurring smectite clay nanoparticles) and a therapeutic agent (for instance, a hydrophilic or hydrophobic therapeutic agent). Also described are methods of releasing a therapeutic agent to a patient using such medical articles, and methods of making such medical articles.

Polymers whose surfaces are modified by endgroups that include amphipathic surface-modifying moieties. An amphipathic endgroup of a polymer molecule is an endgroup that contains at least two moieties of significantly differing composition, such that the amphipathic endgroup spontaneously rearranges its positioning in a polymer body to position the moiety on the surface of the body, depending upon the composition of the medium with which the body is in contact, when that re-positioning causes a reduction in interfacial energy. An example of an amphipathic surface-modifying endgroup is one that has both a hydrophobic moiety and a hydrophilic moiety in a single endgroup. For instance, a hydrophilic poly(ethylene oxide) terminated with a hydrophilic hydroxyl group is not surface active in air when the surface-modifying endgroup is bonded to a more hydrophobic base polymer. If the hydroxyl group on the oligomeric poly(ethylene oxide) is replaced by a hydrophobic methoxy ether terminus, the poly(ethylene oxide) becomes surface active in air, and allows the poly(ethylene oxide) groups to crystallize in the air-facing surface. In this example, immersion in water destroys the crystallinity as the poly(ethylene oxide) sorbs water and the hydrophobic methoxy group retreats below the surface of the polymer. Also disclosed are methods and articles of manufacture that make use of these polymers.

A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

Disclosed are multi-purpose alkali-swellable and alkali soluble associative polymers, which are the polymerization product of a monomer mixture comprising: (a) at least one acidic vinyl monomer; (b) at least one nonionic vinyl monomer; (c) a first associative monomer having a first hydrophobic end group; (d) a monomer selected from the group consisting of a second associative monomer having a second hydrophobic end, a semihydrophobic monomer and a combination thereof; and, optionally, (e) one or more crosslinking monomers or chain transfer agents. When monomer (d) is an associative monomer, the first and second hydrophobic end groups of monomers (c) and (d) have significantly different hydrophobic and / or steric character from one another. The multi-purpose associative polymers surprisingly provide desirable Theological and aesthetic properties in aqueous media.

The present invention describes the method of making anionic ether sulfate surfactants by alkoxylation of a GA using PO and / or EO followed by a sulfation reaction. The GA of the present invention is made by a facile and inexpensive method that involves high temperature base catalyzed dimerization of a linear alcohol. The ether sulfate surfactants of the present invention find uses in EOR applications where it is used for solubilization and mobilization of oil and for environmental cleanup.

The present invention discloses intercalates formed by contacting a layered material, e.g., a phyllosilicate, with an intercalant monomer surface modifier including an alkyl radical having at least 6 carbon atoms and a polymerizable monomer, oligomer or polymer. The intercalant monomer surface modifier converts the interlayer region of the layered materials from hydrophilic to hydrophobic, therefore, polymerizable monomers, oligomers or polymers can be easily intercalated into the interlayer spacing. The co-presence of the intercalant monomer surface modifier and polymerizable monomer, oligomer or polymer provide an environment for more polymerizable monomers, oligomers or polymers to be intercalated into the interlayer spacing and the intercalates are readily exfoliated into polymer matrices to form nanocomposites. The nanocomposites (e.g., epoxy-clay) prepared from the intercalates demonstrated enhanced mechanical, thermal and chemical resistance compared with pristine polymer matrices.

An odor-inhibiting fiber having a cellulosic fiber and an odor-inhibiting formulation. The odor-inhibiting formulation may contain an odor-inhibiting agent, such as a biocide, an enzyme, a urease inhibitor. The odor-inhibiting formulation also may contain a liquid carrier such as a hydrophobic or hydrophilic organic liquid, or a mixture of a hydrophobic and hydrophilic organic liquid. The cellulosic fiber is impregnated with the odor-inhibiting formulation to produce fiber having odor-inhibiting characteristics. The resultant odor-inhibiting fiber is useful in making absorbent articles with odor-inhibiting characteristics. The fiber of the embodiments prevents odor by inhibiting bacteria growth and ammonia production, especially when used in an absorbent article such as a diaper or adult incontinence device.

The present invention relates to formulations and methods for the mucosal and parenteral administration of lipid particles an suspensions. The formulations of this invention are stable lipid particles useful for oral delivery of water-insoluble therapeutic agents, vaccines and diagnostics. The compositions of this invention promote the mucosal absorption of biologically active molecules across mucosal epithelial barriers. Stabilization of lipid particles is achieved by coating the hydrophobic central core with a polymer shell. The polymer shell can include bioadhesive agents, ligands, and absorption promoting agents. This invention relates to oral drug delivery systems for hydrophobic drugs, and in particular is concerned with improving the bioavailability of hydrophobic drugs from such systems. Using this system, anticancer drugs such as taxanes are orally effective.

A water soluble, biodegradable reverse thermal gelation system comprising a mixture of at least two types of tri-block copolymer components is disclosed. The tri-block copolymer components are made of a hydrophobic biodegradable polyester A-polymer block and a hydrophilic polyethylene glycol B-polymer block. The drug release and gel matrix erosion rates of the biodegradable reverse thermal gelation system may be modulated by various parameters such as the hydrophobic / hydrophilic component contents, polymer block concentrations, molecular weights and gelation temperatures, and weight ratios of the tri-block copolymer components in the mixture.

Hydrophobic α(1→4)glucopyranose polymers with enhanced degradation properties are described. Between the α(1→4)glucopyranose polymeric portion and the hydrophobic portion exists a linker portion having a silyl ether chemistry that facilitates degradation of the polymer. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo at an increased rate. Matrices including and capable of releasing a bioactive agent in vivo are also described.

A composition of matter comprising a water-swellable IPN or semi-IPN including a hydrophobic thermoset or thermoplastic polymer and an ionic polymer, articles made from such composition and methods of using such articles. The invention also includes a process for producing a water-swellable IPN or semi-IPN from a hydrophobic thermoset or thermoplastic polymer including the steps of placing an ionizable monomer solution in contact with a solid form of the hydrophobic thermoset or thermoplastic polymer; diffusing the ionizable monomer solution into the hydrophobic thermoset or thermoplastic polymer; and polymerizing the ionizable monomers to form a ionic polymer inside the hydrophobic thermoset or thermoplastic polymer, thereby forming the IPN or semi-IPN.

The present invention relates to multi-functional topical delivery systems for providing long-lasting delivery of fragrance as. well as skin-supporting and / or pharmaceutically active ingredients comprising (i) an oil phase; (ii) an aqueous phase; (iii) phenoxyethanol at a concentration of from about 2.0% to about 2.7% based on the total weight of the composition; (iv) an effective exfoliating amount of a hydrophobic hydroxycarboxylic acid selected from the group consisting of orthohydroxybenzoic acid, hydroxycarboxylic acids containing a C12-C24 fatty acid esterified to the alpha carbon hydroxyl group, hydroxycarboxylic acids containing a C12-C24 fatty alcohol esterified to a carboxyl group; (v) a non-ionic emulsifier having an HLB of from about 7 to about 10; (vi) a fragrance composition; and (vii) at least one skin-supporting or dermatopharmaceutically active agent.

A nano-particle composition including a polar core and a hydrophobic surface layer is provided. The nano-particles have a mean average diameter less than about 100 nm. Methods are disclosed for making and using the nano-particles. The nano-particles can be modified via, for example, hydrogenation or functionalization. The nano-particles can advantageously be incorporated into rubbers, elastomers, and thermoplastics.

A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Coating compositions for producing hydrophobic or super-hydrophobic surfaces and olephobic or super-olephobic surfaces, and to processes for producing such surfaces. In particular, the present invention relates to hydrophobic or olephobic powder coatings and their use for transforming surfaces of articles into hard-to-wet and self-cleaning surfaces.

The present invention relates to personal care compositions, especially those personal care compositions in the form of an article that is a porous, dissolvable solid structure. The article has a hydrophobic surface-resident coating that can provide enhanced deposition efficiency of hydrophobic actives contained therein.

A therapeutic agent delivery implant for implantation into a patient's body comprises a resilient or flexible, at least partially hydrophobic reticulated elastomeric support scaffold; and a hydrophilic coating arranged on said scaffold, wherein said coating contains one or more therapeutic agents for release within the patient. Optionally the coating can contain microspheres or enzymes. In a preferred embodiment, the scaffold comprises a hydrophobic polyurethane, the coating comprises a hydrophilic polyurethane, and the implant has a hemispherical, bullet, football, cylindrical, spherical, or irregular shape. The implant can be delivered through a rigid or flexible delivery instrument that deploys the implant at a desirable site, whereby the implant expands to a size and shape substantially similar to its size and shape before insertion.

The invention discloses a super hydrophobic anti-icing coating and a preparation method thereof, and is realized by preparing a fluorine contained acrylic resin and combining the fluorine contained acrylic resin with organosilicon resin and nano particles. In a scheme of the invention, the fluorine contained acrylic resin has small surface energy and strong hydrophobicity. The organosilicon resin utilizes effect of -CH3 on a surface thereof and small polarity to substantially reduce contact angle hysteresis. The fluorine contained acrylic resin can crosslink and solidify with the nano particles and active groups in the organosilicon resin to form a composite network. The invention can overcome defects of complex technology, high costs and unsuitability for large scale usage of an ordinary method for preparing a super hydrophobic coating; and the prepared coating can realize super hydrophobic anti-icing effect through a regular spraying method.